21.83 USD
↘ 0.37 (1.67%)AT CLOSE (11:59 AM EDT)
Viridian Therapeutics, Inc. Common Stock
VRDNNASDAQ • USD
21.73
↘ 0.10 (0.45%)
POST MARKET (AS OF 07:55 PM EDT)
Post Market
AS OF 07:55 PM EDT
21.73
↘ 0.10 (0.45%)
Market: CLOSED
Viridian Therapeutics, Inc. Common Stock (VRDN) trades at $21.84 per share. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. On the valuation front, VRDN trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.
Technical & fundamental data as of Sep 15, 2026.
Open?$21.98
High?$22.14
Low?$21.40
Prev. Close?$22.20
Volume?1.2M
Avg. Volume?1.5M
VWAP?$21.64
Rel. Volume?0.80x
Bid / Ask
Bid?$20.51 × 300
Ask?$22.95 × 100
Spread?$2.44
Midpoint?$21.73
Valuation & Ratios
Market Cap?2.5B
Shares Out?113.3M
Float?95.5M
Float %?86.5%
P/E Ratio?N/A
P/B Ratio?3.74
EPS?-$2.95
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Employees
252
Market Cap
2.5B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2014-06-18
Address
221 CRESCENT STREET
WALTHAM, MA 02453
Phone: 617.272.4600
WALTHAM, MA 02453
Phone: 617.272.4600
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?12
Z-Score?17
Momentum?75
Short Sent.?19
Piotroski F-Score?2/9Weak
Altman Z-Score?1.36Distress
Confidence?62%Moderate
Short InterestSqueeze Risk
Short % of Float?20.42%Squeeze Risk
Short Interest?19.5M
Days to Cover?16.6
Free Float95.5M
Avg Daily Volume1.2M
Settlement Date2026-08-31
Financial Health
Current Ratio?16.95Strong
Quick Ratio?16.95Strong
Cash Ratio?2.59Strong
Debt/Equity?0.54Moderate
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score58/100
P/E?N/A▾
P/B?3.74FAIR▾
Peers100
S&P47
P/S?34.77HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-6.6CHEAP▾
S&P97
EV/Sales?37.45HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?-50.5%WEAK▾
S&P3
ROA?-30.5%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-335039000
Enterprise Value?$2.7B
Fundamentals ratios updated end of day